KemPharm Gets FDA Orphan Drug Designation for Serdexmethylphenidate for Idiopathic Hypersomnia
The drug developer expects to initiate a phase 2 clinical trial in patients with idiopathic hypersomnia before year-end 2022 and a second trial in patients with narcolepsy in 2023.